Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes

  • End date
    Apr 1, 2023
  • participants needed
  • sponsor
    Better Therapeutics
Updated on 1 November 2021


BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) in patients with type 2 diabetes.


The study will utilize an open-label, pragmatic design to confirm and characterize the safety and efficacy of BT-001 used in addition to standard of care (SOC) in patients with type 2 diabetes. The screening period will consist of review of Electronic Health Record (EHR) for participants that meet inclusion criteria and telephonic outreach.

Once confirmed consented, patients will then be given access to BT-001 for 90 days with an opportunity to continue using the product for an additional 275 days.

Participants will continue their standard of care with their provider in addition to using BT-001.

Condition Type2 Diabetes
Treatment BT-001
Clinical Study IdentifierNCT05094401
SponsorBetter Therapeutics
Last Modified on1 November 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of Type2 Diabetes
Possess a smart phone (iPhone or Android only) capable of running the smart phone application (App) used in the study
HbA1c level 7% and <11%, as determined by the HbA1c measured within the previous 12 months
Willing to use a glucometer for self-monitoring blood glucose while using the study App
Capable of giving informed consent in English, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria

Unable to understand, consent to, or comply with the study protocol for any reason, including the inability to read or comprehend English. The behavioral intervention mechanisms, including educational materials and digital tools, are only available in English at this time
Currently taking prandial (mealtime) insulin
Currently experiencing heart failure of New York Heart Association Class IV
Currently experiencing stage 4 or 5 chronic kidney disease
Currently on kidney dialysis (hemo or peritoneal)
Currently on the list for an organ transplant or previously received a transplant of any organ
Currently receiving treatment for cancer
For women only: pregnant or lactating or having the intention of becoming pregnant during the time frame of the study
Presumed or confirmed COVID-19 diagnosis within 90 days prior to study enrollment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note